The proportion of CD4+ cells in the tumor infiltrating CD45+ leukocytes was 28.7% in 1D11-treated mice, markedly higher than that in control IgG1- treated mice (22.6%, P<0.05, Fig C). The gene discussed is PTPRC; the disease is neoplasm.